CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Ann Oncol · 2016 · PMC4803454 · PMID 26802160

Europe PMC DOI

hedged sentence

0.4040

closest p · 8.1× alpha

0.4040

boldest claim

The sentences

did not reach statistical significanceP = 0.404not close (p > 0.1)

A similar trend was observed in the Gem-alone arm, although it did not reach statistical significance [median 9.4 versus 7.1 months; HR 0.84 (95% CI 0.56–1.27); P = 0.404].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.